TB Archives – Page 33 of 47 – Treatment Action Group

Open Letter: Appreciation for Sanofi US Committing to Lower Price of Rifapentine

December 18, 2013
Dorrit Walsh

This letter from CRAG (TB Community Research Advisors Group) and TAG was sent to Anne Whitaker, President, North America Pharmaceuticals of Sanofi US. It commends Sanofi for making this commitment to lower the price of rifapentine for Public Health Service…

2013 TAG Update

December 13, 2013
Chad Cipiti

TAG’s annual review of progress we’ve made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.

CRAG, TAG Welcome Sanofi U.S. Commitment to Reduce the Price of Tuberculosis Drug Rifapentine

December 12, 2013
Chad Cipiti

The Community Research Advisors Group (CRAG) and Treatment Action Group (TAG) welcome the Sanofi U.S. decision to lower the price of the tuberculosis (TB) drug rifapentine to $32 per 32-tablet blister pack. The company indicates that the new price will become effective in January 2014 under 340(b) Public Health Service pricing.

TAG, CRAG, and TB CAB Letter Calling for Compassionate Use Program for Delamanid

December 4, 2013
Dorrit Walsh

TAG, CRAG, and the TB CAB issues urgent appeal for Otsuka to initiate its long overdue compassionate use program by the end of 2013.

TAG Applauds $12 Billion Replenishment of Global Fund to Fight AIDS, Tuberculosis and Malaria

December 3, 2013
Chad Cipiti

Treatment Action Group applauds the donors who have helped make it possible to save more lives by raising a record-breaking $12 billion for the Global Fund to Fight AIDS, Tuberculosis and Malaria over the next three years. TAG also commends the Obama administration for its generous match of one dollar for every two dollars contributed by other donors, which helped to drive up funding commitments in the current replenishment round.

Treatment Action Group Applauds European Approval of New Drug to Fight Tuberculosis, Demands Expanded Access and Affordable Pricing

November 22, 2013
Chad Cipiti

Treatment Action Group (TAG) congratulates the Committee for Medicinal Products for Human Use (CHMP) for its recommendation to the European Medicines Agency (EMA) to grant marketing approval to delamanid, a new drug for multidrug-resistant tuberculosis (MDR-TB) now in phase III clinical trials. MDR-TB treatment options that do not include new drugs are long, toxic, difficult to tolerate, and often ineffective.

2013 Symposium: Cascades – Improving TB Care

November 19, 2013
Chad Cipiti

The Treatment Action Group (TAG) “Cascades: Improving TB Care” symposium was held on November 1 at the 2013 International Union World Conference on Lung Health in Paris, France. Cosponsored by TAG, Médecins Sans Frontières (MSF), Partners In Health (PIH), the…

Tuberculosis Behind the Numbers Video Series

November 1, 2013
Chad Cipiti

Mike Frick of Treatment Action Group (TAG) and Audrey Zhang of Harvard College argue that patient-centered approaches in treatment for drug-resistant and drug-sensitive tuberculosis are needed. View Webinar Lindsay McKenna and Colleen Daniels of Treatment Action Group (TAG) describe the…

New Approaches to Drug-Resistant Tuberculosis

October 30, 2013
Chad Cipiti

A Double Blow: Private-Sector Funding for TB Research Drops Sharply Amid Severe Public-Sector Budget Cuts

October 29, 2013
Chad Cipiti

The 2013 Report on Tuberculosis Research Funding Trends, 2005–2012 finds that funding for tuberculosis research and development (TB R&D) dropped by US$30.4 million compared with 2011—the first time funding has fallen since TAG began tracking investments in 2005. Funding declined for diagnostic, drug, vaccine, and operational research, increasing the likelihood that new tools to fight TB will remain out of reach for the 8.7 million people who develop TB each year.